Renal Recovery following Liposomal Amphotericin B-Induced Nephrotoxicity

Table 2

Univariate Cox models.

Characteristic	Summary Data	HR for At Least Partial Recovery	p-value	HR for Complete Recovery	p-value
Age, mean (SD)	56 (14.6)	0.99 (0.81, 1.20)	0.88	0.88 (0.69, 1.13)	0.32
Sex
Male, n (%)	63 (64.3)	0.92 (0.52, 1.63)	0.78	0.84 (0.41, 1.70)	0.62
Female, n (%)	35 (35.7)	1.00
Race
Caucasian, n (%)	87 (35.7)	0.70 (0.30, 1.63)	0.40	0.56 (0.22, 1.46)	0.24
Other, n (%)	11 (11.2)	1.00
BMI per kg/m^2, mean (SD)	28.5 (7)	1.03 (0.98, 1.07)	0.23	1.01 (0.96, 1.06)	0.82
Pretreatment serum creatinine per mg/dL, mean (SD)	0.9 (0.3)	1.10 (0.33, 3.73)	0.88	1.27 (0.27, 6.03)	0.76
Renal replacement therapy requirement
Yes, n (%)	8 (8.2)	0.47 (0.11, 1.94)	0.30	5.48 (0.32, 93.61)	0.24
No, n (%)	90 (91.8)	1.00
Daily LAmB dose in mg at time of AKI (per 100 mg), mean (SD)	288.5 (244)	0.97 (0.85, 1.10)	0.59	0.94 (0.80, 1.03)	0.43
Pre-AKI cumulative LAmB dose (per 5,000 mg), mean (SD)	2445.2 (3144.1)	0.87 (0.51, 1.48)	0.60	0.87 (0.46, 1.63)	0.66
Cumulative LAmB dose (per 5,000 mg), mean (SD)	4985.8 (6659.8)	0.84 (0.58, 1.21)	0.36	0.81 (0.50, 1.31)	0.39
Concomitant Vancomycin
Yes, n (%)	32 (32.7)	0.79 (0.19, 3.28)	0.74	1.50 (0.35, 6.48)	0.59
No, n (%)	66 (67.3)	1.00
Total Concomitant Nephrotoxins (per 1 nephrotoxin)		1.36 (0.82, 2.25)	0.24	1.49 (0.81, 2.71)	0.20

indicates time-dependent variables.
HR per decade increase.
LAmB prior to AKI+ LAmB after AKI (time dependent).